Greenovation Biotech GmbH Announces Completion Of Its Phase I Safety Study For moss-aGal Targeting Fabry Disease

Greenovation Biotech GmbH announces completion of its Phase I safety study for moss-aGal targeting Fabry disease.

FREIBURG, Germany, October 17, 2017  Greenovation Biotech GmbH, a clinical-stage biopharmaceutical company developing therapies to treat orphan diseases today announces completion of its Phase I moss-aGal study in Fabry disease (FD).Greenovation expects to report data from the study later this year.

The Phase I study was designed as a single dose administered in six patients suffering from FD. Primary endpoints were safety and pharmacokinetics. The patients were monitored over 28 days. The single dose of moss-aGal was well tolerated by patients. 

Moss-aGal is the first clinical product produced in Greenovation`s moss-based technology and therefore the first ever moss-made drug candidate tested in humans.

We would particularly like to thank the patient volunteers who participated in this clinical study. The results may help to develop a drug that will hopefully improve the treatment of Fabry disease in future. In preclinical studies moss-aGal demonstrated pharmacodynamic differences as compared to approved drugs. These will hopefully translate to improvements in patients’ quality of life. The expected positive Phase I results will pave the way for quick initiation of Phase II/III studies.” says Dr. Thomas Frischmuth, CEO of Greenovation.

Contact and further information:
Greenovation Biotech GmbH
Manon Kirstein,
Tel: +49 761 470 99 0



Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Greenovation Biotech GmbH

Greenovation develops next-generation therapeutics using its proprietary BryoTechnologyplatform. The company aims to optimize the production of highly-efficient glycoproteins for the treatment of diseases.

Greenovation is a privately-owned biopharmaceutical company based in Heilbronn, Germany. It was founded in 1999 by Prof. Dr. Ralf Reski and Prof. Dr. Gunter Neuhaus. Today, Greenovation Biotech GmbH is majority-owned by Zukunftsfonds Heilbronn and L EigenkapitalAgentur (Karlsruhe).